[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Checkmab S.r.l.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100580830","novel-targets-for-the-development-of-monoclonal-antibodies-for-immunotherapy-100580830",false,"NCT06842407","Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)","Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)","Immuno-ab","Inclusion Criteria:\n\n* blood donors\n* age of 18 years or more\n* able to sign informed consent\n\nExclusion Criteria:\n\n* age below 18 years\n* Positive for HIV, HCV, HBV\n* not suitable for blood donation\n* not able to understand or sign informed consent",true,"ALL","18 Years",{"count":21,"type":22},600,"ESTIMATED","OBSERVATIONAL","The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.",[26],"Healthy Donors","RECRUITING","2025-02-19",{"date":30,"type":31},"2025-02-24","ACTUAL",{"date":33,"type":31},"2023-04-01",{"date":35,"type":22},"2026-06-30",{"name":37,"class":38},"Checkmab S.r.l.","INDUSTRY",""]